1. Development of potent class II transactivator gene delivery systems capable of inducing de novo MHC II expression in human cells, in vitro and ex vivo
- Author
-
Parichat Duangkhae, Ernesto T. A. Marques, Eduardo J. M. Nascimento, Isabelle F. T. Viana, A. J. Da Silva Duarte, Rafael Dhalia, Robbie B. Mailliard, Paula Ordonhez Rigato, Telma Miyuki Oshiro, Bruno Douradinha, Mariana L. Palma, and Simon M. Barratt-Boyes
- Subjects
0301 basic medicine ,Genes, MHC Class II ,Genetic Vectors ,chemical and pharmacologic phenomena ,Gene delivery ,Major histocompatibility complex ,03 medical and health sciences ,Transactivation ,0302 clinical medicine ,Antigen ,Genetics ,CIITA ,Humans ,Molecular Biology ,Gene ,Skin ,biology ,Lentivirus ,Gene Transfer Techniques ,Genetic Therapy ,Molecular biology ,Cell biology ,030104 developmental biology ,HEK293 Cells ,Cell culture ,biology.protein ,Trans-Activators ,Molecular Medicine ,Ex vivo ,030215 immunology ,HeLa Cells - Abstract
Class II transactivator (CIITA) induces transcription of major histocompatibility complex (MHC) II genes and can potentially be used to improve genetic immunotherapies by converting non-immune cells into cells capable of presenting antigens to CD4+ T cells. However, CIITA expression is tightly controlled and it remains unclear whether distinct non-immune cells differ in this transactivator regulation. Here we describe the development of gene delivery systems capable of promoting the efficient CIITA expression in non-immune cell lines and in primary human cells of an ex vivo skin explant model. Different human cell types undergoing CIITA overexpression presented high-level de novo expression of MHC II, validating the delivery systems as suitable tools for the CIITA evaluation as a molecular adjuvant for gene therapies.
- Published
- 2016